Lung Adenocarcinoma - Pipeline Review, H2 2015 Is

Released
Lung Adenocarcinoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Lung
Adenocarcinoma - Pipeline Review, H2 2015 , provides an overview of the Lung Adenocarcinoma s
therapeutic pipeline. This report provides comprehensive information on the therapeutic development
for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases. It also reviews key players
involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage
and discontinued projects. Global Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and
information sourced from Global Markets Directs proprietary databases, Company/University websites,
SEC filings, investor presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct s team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of
processes that ensures that all the profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box and clinical trials registries
tracking ensure that the most recent developments are captured on a real time basis. The report
enhances decision making capabilities and help to create effective counter strategies to gain
competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated disease. Scope - The report provides a
snapshot of the global therapeutic landscape of Lung Adenocarcinoma - The report reviews key pipeline
products under drug profile section which includes, product description, MoA and R&D brief, licensing
and collaboration details & other developmental activities - The report reviews key players involved in
the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects - A review of the Lung
Adenocarcinoma products under development by companies and universities/research institutes based
on information derived from company and industry-specific sources - Pipeline products coverage based
on various stages of development ranging from pre-registration till discovery and undisclosed stages - A
detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lung
Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically
significant competitor information, analysis, and insights to formulate effective R&D development
strategies - Identify emerging players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the
focus areas of leading companies - Identify and understand important and diverse types of therapeutics
under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying
key players of the most promising pipeline - Devise corrective measures for pipeline projects by
understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and
design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope - Modify the therapeutic
1

portfolio by identifying discontinued projects and understanding the factors that drove them from
pipeline.
with TOC
@ http://www.idatainsights.com/reports-landing-page.php?id=173379/lungadenocarcinoma-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173379/lung-adenocarcinoma-pipeline-review-h2-2015

Table of Contents

Introduction 8
Global Markets Direct Report Coverage 8
Lung Adenocarcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Lung Adenocarcinoma - Overview 10
Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 11
Lung Adenocarcinoma - Therapeutics under Development by Companies 12
Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 14
Lung Adenocarcinoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Lung Adenocarcinoma - Products under Development by Companies 18
Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 19
Lung Adenocarcinoma - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Astex Pharmaceuticals, Inc. 21
AstraZeneca Plc 22
AVEO Pharmaceuticals, Inc. 23
Axelar AB 24
2

Bayer AG 25
Boehringer Ingelheim GmbH 26
Eisai Co., Ltd. 27
Genentech, Inc. 28
Hanmi Pharmaceuticals, Co. Ltd. 29
Immunomedics, Inc. 30
Incyte Corporation 31
Johnson & Johnson 32
Morphotek, Inc. 33
Pfizer Inc. 34
Sanofi 35
VG Life Sciences, Inc. 36
Vichem Chemie Research Ltd. 37
Lung Adenocarcinoma - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
afatinib dimaleate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AV-203 - Drug Profile 55
Product Description 55
3

Mechanism of Action 55
R&D Progress 55
AXL-1717 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AZD-6738 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BAY-1163877 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
dacomitinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DBPR-112 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
EB-102 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65

farletuzumab - Drug Profile 66

Product Description 66
Mechanism of Action 66
R&D Progress 66
hydroxychloroquine + sorafenib tosylate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JNJ-42756493 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
lenvatinib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MAG-Tn3 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
poziotinib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases Drug Profile 81
Product Description 81

Mechanism of Action 81
R&D Progress 81
ruxolitinib phosphate - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SAR-408701 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule for Cancer - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile
89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91

SNX-5422 - Drug Profile 92

Product Description 92
Mechanism of Action 92
R&D Progress 92
solitomab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
TdCyd - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Vaccine for Oncology - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
VAL-401 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Lung Adenocarcinoma - Recent Pipeline Updates 99
Lung Adenocarcinoma - Dormant Projects 129
Lung Adenocarcinoma - Product Development Milestones 130
7

Featured News & Press Releases 130

May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015
ASCO Annual Meeting 130
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132"

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173379/lungadenocarcinoma-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects